Independent investment research firm, Bioshares, rated Patrys as one of its top six stock picks for 2021,
stating: ‘In general, antibodies are unable to cross the blood-brain barrier, so an antibody that overcomes
that limitation, along with the potential to hit a key target, such as one related to glioblastoma (a brain
cancer), is significant. Patrys is in the possession of a potentially powerful new approach for
addressing difficult-to-treat cancers, such as brain, melanoma, breast, prostate and ovarian cancers.’
https://www.patrys.com/site/in-the-news/Bioshares874rbpPAB_18%20December%202020.pdf
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.167M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $13.07K | 8.35M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 61 | 205045293 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 111265026 | 40 |
View Market Depth
| Last trade - 16.10pm 16/09/2025 (20 minute delay) ? |
| PAB (ASX) Chart |